300181 佐力药业
已收盘 10-10 15:00:00
资讯
新帖
简况
股市必读:佐力药业(300181)9月30日董秘有最新回复
证券之星 · 10-08 20:10
股市必读:佐力药业(300181)9月30日董秘有最新回复
股市必读:佐力药业(300181)9月19日董秘有最新回复
证券之星 · 09-21
股市必读:佐力药业(300181)9月19日董秘有最新回复
佐力药业:前五大客户大部分为医药商业公司
证券之星 · 09-19
佐力药业:前五大客户大部分为医药商业公司
佐力药业:9月12日组织现场参观活动,中信建投、厚宏汇智等多家机构参与
证券之星 · 09-15
佐力药业:9月12日组织现场参观活动,中信建投、厚宏汇智等多家机构参与
佐力药业:医药固体制剂数字化车间预计年底前达到可使用状态
第一财经 · 09-14
佐力药业:医药固体制剂数字化车间预计年底前达到可使用状态
股市必读:佐力药业(300181)9月5日披露最新机构调研信息
证券之星 · 09-07
股市必读:佐力药业(300181)9月5日披露最新机构调研信息
佐力药业:9月4日组织现场参观活动,财通基金、和谐汇一等多家机构参与
证券之星 · 09-07
佐力药业:9月4日组织现场参观活动,财通基金、和谐汇一等多家机构参与
佐力药业:凌意生物的帕金森管线LY-N001研发工作正在持续推进中
格隆汇 · 09-07
佐力药业:凌意生物的帕金森管线LY-N001研发工作正在持续推进中
股市必读:佐力药业(300181)9月3日董秘有最新回复
证券之星 · 09-03
股市必读:佐力药业(300181)9月3日董秘有最新回复
佐力药业:公司目前在研的创新药包括灵香片正在开展Ⅱ期临床试验
证券之星 · 09-03
佐力药业:公司目前在研的创新药包括灵香片正在开展Ⅱ期临床试验
股市必读:佐力药业(300181)8月27日董秘有最新回复
证券之星 · 08-27
股市必读:佐力药业(300181)8月27日董秘有最新回复
佐力药业:聚卡波非钙片IBS-D注册临床研究推进中
证券之星 · 08-27
佐力药业:聚卡波非钙片IBS-D注册临床研究推进中
佐力药业:股东人数查询需提供持股证明
证券之星 · 08-24
佐力药业:股东人数查询需提供持股证明
佐力药业(300181)2025年中报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 08-20
佐力药业(300181)2025年中报简析:营收净利润同比双双增长,盈利能力上升
佐力药业最新公告:上半年净利润同比增长26.16%
证券之星 · 08-19
佐力药业最新公告:上半年净利润同比增长26.16%
8月11日佐力药业涨7.83%,汇添富中证中药ETF基金重仓该股
证券之星 · 08-11
8月11日佐力药业涨7.83%,汇添富中证中药ETF基金重仓该股
佐力药业涨7.83%,东吴证券一个月前给出“买入”评级
证券之星 · 08-11
佐力药业涨7.83%,东吴证券一个月前给出“买入”评级
佐力药业:乌灵胶囊用于治疗失眠、改善焦虑抑郁状态等心身疾病
证券之星 · 08-08
佐力药业:乌灵胶囊用于治疗失眠、改善焦虑抑郁状态等心身疾病
佐力药业:乌灵系列产品均是独家品种
证券之星 · 08-08
佐力药业:乌灵系列产品均是独家品种
佐力药业:乌灵胶囊用于心肾不交所致的失眠
证券之星 · 07-28
佐力药业:乌灵胶囊用于心肾不交所致的失眠
加载更多
公司概况
公司名称:
浙江佐力药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-02-22
主营业务:
浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵系列(乌灵胶囊、灵泽片、灵莲花颗粒)、百令系列(百令片、百令胶囊)、中药饮片及中药配方颗粒、聚卡波非钙片。2025年7月,由北京市经济和信息化局等单位联合主办、中国医药工业信息中心承办的2025第42届全国医药工业信息年会,公司荣膺2025年中国医药工业企业社会责任优秀案例榜单。
发行价格:
23.50
{"stockData":{"symbol":"300181","market":"SZ","secType":"STK","nameCN":"佐力药业","latestPrice":18.19,"timestamp":1760079792000,"preClose":17.86,"halted":0,"volume":16291975,"delay":0,"changeRate":0.0185,"floatShares":603000000,"shares":701000000,"eps":0.8344,"marketStatus":"已收盘","change":0.33,"latestTime":"10-10 15:00:00","open":17.86,"high":18.33,"low":17.78,"amount":296000000,"amplitude":0.0308,"askPrice":18.2,"askSize":976,"bidPrice":18.19,"bidSize":1976,"shortable":0,"etf":0,"ttmEps":0.8344,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760319000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.86,"symbolType":"stock","openAndCloseTimeList":[[1760059800000,1760067000000],[1760072400000,1760079600000]],"highLimit":19.65,"lowLimit":16.07,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":701387335,"isCdr":false,"pbRate":4.12,"roa":"--","peRate":21.800096,"roe":"12.85%","epsLYR":0.73,"committee":-0.125175,"marketValue":12758000000,"turnoverRate":0.027,"status":0,"floatMarketCap":10967000000},"requestUrl":"/m/hq/s/300181","defaultTab":"news","newsList":[{"id":"2574978972","title":"股市必读:佐力药业(300181)9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574978972","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574978972?lang=zh_cn&edition=full","pubTime":"2025-10-09 04:10","pubTimestamp":1759954224,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘,佐力药业报收于17.8元,上涨0.39%,换手率1.16%,成交量7.01万手,成交额1.24亿元。董秘最新回复投资者: 请问公司截止2025年9月20股东人数为多少人?公司根据信息披露相关规定在定期报告中披露对应时点的股东人数,您可关注公司已披露的定期报告。交易信息汇总资金流向9月30日主力资金净流入330.86万元,占总成交额2.66%;游资资金净流出459.74万元,占总成交额3.69%;散户资金净流入128.88万元,占总成交额1.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900001171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0239","BK0077"],"gpt_icon":0},{"id":"2569222175","title":"股市必读:佐力药业(300181)9月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2569222175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569222175?lang=zh_cn&edition=full","pubTime":"2025-09-22 01:13","pubTimestamp":1758474790,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,佐力药业报收于17.64元,下跌0.9%,换手率1.67%,成交量10.1万手,成交额1.78亿元。董秘最新回复投资者: 董秘您好,我看网上说乌灵参有安神止血降压的功效,公司能否考虑研发以乌灵参为主要原料的中药高血压新药,以造福广大高血压患者?公司二级子公司佐力创新医疗持有科济药业28,385,012股股份。当日关注点来自交易信息汇总:9月19日主力资金净流出3494.6万元,散户资金净流入2920.15万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200000413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0239","BK0042","BK0077"],"gpt_icon":0},{"id":"2568230568","title":"佐力药业:前五大客户大部分为医药商业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2568230568","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568230568?lang=zh_cn&edition=full","pubTime":"2025-09-19 15:12","pubTimestamp":1758265943,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)09月19日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,2024年年报数据,前五大客户销售数据合计占比48%,第一大客户占比18%,为什么这么高?咱们主要客户都是医院,按常理推测,采购比较分散,单一一家不会这么高。佐力药业回复:您好!公司前五大客户大部分为医药商业公司。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900017677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","300181","09939","BK1515","BK0077","BK0042","BK0239","BK1574"],"gpt_icon":0},{"id":"2567169304","title":"佐力药业:9月12日组织现场参观活动,中信建投、厚宏汇智等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2567169304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567169304?lang=zh_cn&edition=full","pubTime":"2025-09-15 09:11","pubTimestamp":1757898662,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年9月14日佐力药业发布公告称公司于2025年9月12日组织现场参观活动,中信建投、厚宏汇智、德远投资、北斗星投资、广州图灵、深圳斯比亚、深圳国安投资、广州顺从投资、深圳世纪量子资本、湖南汇智融达、知远资本、浙江思悦、鸣则投资、静水泉基金、珠海德润恒泰投资、财沣投资、嘉伦投资参与。佐力药业主营业务:药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500002469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","601066","BK0042","BK0276","BK0239","300181"],"gpt_icon":0},{"id":"2567151866","title":"佐力药业:医药固体制剂数字化车间预计年底前达到可使用状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2567151866","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567151866?lang=zh_cn&edition=full","pubTime":"2025-09-14 21:21","pubTimestamp":1757856060,"startTime":"0","endTime":"0","summary":"据证券时报,佐力药业近日在现场参观活动中表示,公司医药固体制剂数字化车间预计年底前达到可使用状态,届时将同步满足胶囊、片剂等剂型产品需求。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-09-14/doc-infqnrnz0365953.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-09-14/doc-infqnrnz0365953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK0239","09939","300181","BK1161","BK0042","BK1574","159938","BK1515"],"gpt_icon":0},{"id":"2565520562","title":"股市必读:佐力药业(300181)9月5日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2565520562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565520562?lang=zh_cn&edition=full","pubTime":"2025-09-08 06:25","pubTimestamp":1757283913,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘,佐力药业报收于18.14元,上涨1.17%,换手率2.34%,成交量14.12万手,成交额2.54亿元。上述措施推动今年上半年院外渠道销售显著增长。根据《2025 年中国睡眠健康调查报告》,中国18岁及以上人群睡眠困扰率达48.5%,叠加老龄化趋势,乌灵胶囊市场潜力较大。院内端方面,乌灵胶囊现覆盖约15000家等级医院,而全国各级医疗机构超百万家,作为国家基本药物,其基层覆盖仍有广阔空间。LY-N001研发持续推进,目前已完成主要临床前研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800001563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0077","BK0239","300181"],"gpt_icon":0},{"id":"2565540857","title":"佐力药业:9月4日组织现场参观活动,财通基金、和谐汇一等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2565540857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565540857?lang=zh_cn&edition=full","pubTime":"2025-09-07 16:01","pubTimestamp":1757232105,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年9月6日佐力药业发布公告称公司于2025年9月4日组织现场参观活动,财通基金王靖萱、和谐汇一朱晨、长江证券张楠、凌意生物郑超一 邓高明参与。凌意生物是一家专注于单基因遗传病源头创新药研发企业,定位为开发具有差异化优势的基因治疗药物。公司于 2025年 4 月向凌意生物增资了 2000 万元。佐力药业主营业务:药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700003643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0042","300181"],"gpt_icon":0},{"id":"2565754997","title":"佐力药业:凌意生物的帕金森管线LY-N001研发工作正在持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2565754997","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565754997?lang=zh_cn&edition=full","pubTime":"2025-09-07 09:13","pubTimestamp":1757207606,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK6022","BK1161","BK1574","BK0077","BK0042","159992","06978","1H8.SI","300181","BK0239","BK6505"],"gpt_icon":0},{"id":"2564130383","title":"股市必读:佐力药业(300181)9月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2564130383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564130383?lang=zh_cn&edition=full","pubTime":"2025-09-04 02:22","pubTimestamp":1756923735,"startTime":"0","endTime":"0","summary":"截至2025年9月3日收盘,佐力药业报收于18.26元,下跌1.4%,换手率2.07%,成交量12.48万手,成交额2.29亿元。公司目前在研的创新药包括灵香片正在开展Ⅱ期临床试验,还有其他治疗方向的3个乌灵系列创新中药正在进行临床前的毒理和药学研究。当日关注点来自交易信息汇总:9月3日主力资金净流出2088.47万元,散户资金净流入4010.94万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400001140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0077","BK0239","300181"],"gpt_icon":0},{"id":"2564364263","title":"佐力药业:公司目前在研的创新药包括灵香片正在开展Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2564364263","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564364263?lang=zh_cn&edition=full","pubTime":"2025-09-03 18:09","pubTimestamp":1756894161,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)09月03日在投资者关系平台上答复投资者关心的问题。投资者提问:公司有创新药吗佐力药业回复:您好!公司主要聚焦于中医药创新药研发,重点围绕乌灵系列品种进行深度研究,积极落实“立项一批、临床一批、上市一 批”的战略布局。公司目前在研的创新药包括灵香片正在开展Ⅱ期临床试验,还有其他治疗方向的3个乌灵系列创新中药正在进行临床前的毒理和药学研究。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300029981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","BK1161","300181","159992","BK0077","BK1574","BK0042"],"gpt_icon":0},{"id":"2562722833","title":"股市必读:佐力药业(300181)8月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2562722833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562722833?lang=zh_cn&edition=full","pubTime":"2025-08-28 03:09","pubTimestamp":1756321771,"startTime":"0","endTime":"0","summary":"截至2025年8月27日收盘,佐力药业报收于19.15元,下跌3.14%,换手率4.64%,成交量28.0万手,成交额5.46亿元。董秘最新回复投资者: 请问,公司ISB一D三期临床结束了没有,AD适应症申报临床了吗?交易信息汇总8月27日,佐力药业的资金流向显示主力资金净流出6954.55万元;游资资金净流入2070.9万元;散户资金净流入4883.65万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800002517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300181","BK0042"],"gpt_icon":0},{"id":"2562992716","title":"佐力药业:聚卡波非钙片IBS-D注册临床研究推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2562992716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562992716?lang=zh_cn&edition=full","pubTime":"2025-08-27 16:57","pubTimestamp":1756285029,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,公司ISB一D三期临床结束了没有,AD适应症申报临床了吗?进展如何?谢谢!佐力药业回复:您好!公司产品聚卡波非钙片的IBS-D注册临床研究正在推进中;乌灵胶囊二次开发正在持续推进中,公司已完成乌灵胶囊改良型新药AD动物药效学研究。谢谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700034777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0239","BK0077"],"gpt_icon":0},{"id":"2561825001","title":"佐力药业:股东人数查询需提供持股证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2561825001","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561825001?lang=zh_cn&edition=full","pubTime":"2025-08-24 18:12","pubTimestamp":1756030335,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业08月24日在投资者关系平台上答复投资者关心的问题。盼你们具体,明确答复。顺祝健康,快乐 【比如截至到2025年8月10日贵公司的股东人数是多少?对于非定期报告时点的股东人数查询,根据《公司章程》及相关法律法规规定,请您本人向公司提供证明您持有公司股份的类别以及持股数量的书面文件,公司将在核实股东身份信息无误后予以提供。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400009899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0077","300181"],"gpt_icon":0},{"id":"2561487896","title":"佐力药业(300181)2025年中报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2561487896","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561487896?lang=zh_cn&edition=full","pubTime":"2025-08-21 06:08","pubTimestamp":1755727689,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期佐力药业发布2025年中报。截至本报告期末,公司营业总收入15.99亿元,同比上升11.99%,归母净利润3.74亿元,同比上升26.16%。按单季度数据看,第二季度营业总收入7.75亿元,同比上升2.6%,第二季度归母净利润1.92亿元,同比上升25.2%。本报告期佐力药业盈利能力上升,毛利率同比增幅0.62%,净利率同比增幅12.93%。持有佐力药业最多的基金为汇添富中证中药ETF,目前规模为18.14亿元,最新净值1.1494,较上一交易日上涨0.63%,近一年上涨13.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100002759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2560160746","title":"佐力药业最新公告:上半年净利润同比增长26.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560160746","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560160746?lang=zh_cn&edition=full","pubTime":"2025-08-19 18:30","pubTimestamp":1755599401,"startTime":"0","endTime":"0","summary":"佐力药业(300181.SZ)发布2025年半年度报告,报告期内公司实现营业收入15.99亿元,同比增长11.99%;归属于上市公司股东的净利润3.74亿元,同比增长26.16%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081900033690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2558630965","title":"8月11日佐力药业涨7.83%,汇添富中证中药ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558630965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558630965?lang=zh_cn&edition=full","pubTime":"2025-08-11 16:26","pubTimestamp":1754900797,"startTime":"0","endTime":"0","summary":"证券之星消息,8月11日佐力药业涨7.83%创60日新高,收盘报20.39元,换手率7.64%,成交量46.05万手,成交额9.21亿元。重仓佐力药业的前十大公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共16家,其中持有数量最多的公募基金为汇添富基金的汇添富中证中药ETF。汇添富中证中药ETF目前规模为18.14亿元,最新净值1.1147,较上一交易日上涨0.34%,近一年上涨7.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081100025851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300181","BK0042","BK0077","560080","159647"],"gpt_icon":0},{"id":"2558630914","title":"佐力药业涨7.83%,东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2558630914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558630914?lang=zh_cn&edition=full","pubTime":"2025-08-11 16:26","pubTimestamp":1754900789,"startTime":"0","endTime":"0","summary":"今日佐力药业涨7.83%,收盘报20.39元。2025年7月10日,东吴证券研究员朱国广,苏铖发布了对佐力药业的研报《2025年半年度业绩预告点评:利润端持续亮眼,战略布局“乌灵菌+”,打开中期第二增长曲线》,该研报对佐力药业给出“买入”评级。研报中预计2025-2027年公司归母净利润为6.55/8.41/10.41亿元,对应PE估值为20/16/13X。展望下半年,随着广东联盟扩围接续以及湖北中成药集采的陆续执行,公司乌灵胶囊、百令系列放量均有望提速。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081100025844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","601555"],"gpt_icon":0},{"id":"2557254791","title":"佐力药业:乌灵胶囊用于治疗失眠、改善焦虑抑郁状态等心身疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2557254791","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557254791?lang=zh_cn&edition=full","pubTime":"2025-08-08 17:45","pubTimestamp":1754646343,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业08月08日在投资者关系平台上答复投资者关心的问题。公司产品乌灵胶囊用于治疗失眠、改善焦虑抑郁状态等心身疾病,有明确的GABA作用机理、基因芯片研究和Meta分析结果支持,已经进入多个相关的临床指南和专家共识,很多临床专家也会针对本科室的特定患者人群,使用乌灵胶囊进一步开展相关的临床研究,发挥中医药的优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800028553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0239","BK0077"],"gpt_icon":0},{"id":"2557054796","title":"佐力药业:乌灵系列产品均是独家品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2557054796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557054796?lang=zh_cn&edition=full","pubTime":"2025-08-08 17:42","pubTimestamp":1754646135,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)08月08日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司乌灵系列产品是否是世界独家?佐力药业回复:您好!公司乌灵系列产品均是独家品种。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800028427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","300181","BK0042"],"gpt_icon":0},{"id":"2554472166","title":"佐力药业:乌灵胶囊用于心肾不交所致的失眠","url":"https://stock-news.laohu8.com/highlight/detail?id=2554472166","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554472166?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:24","pubTimestamp":1753691059,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问:基孔肯雅热症状是高烧,剧烈关节痛,部分患者会出现长达数月甚至数年的慢性关节痛。请问乌灵胶囊是否有助于患者入眠?佐力药业回复:您好!公司产品乌灵胶囊具有补肾健脑,养心安神的作用,用于心肾不交所致的失眠、心悸心烦、神疲乏力、腰膝酸软等。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800021115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0077","300181"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1760138266053,"stockEarnings":[{"period":"1week","weight":0.0219},{"period":"1month","weight":-0.0082},{"period":"3month","weight":-0.035},{"period":"6month","weight":0.1454},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.2281}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.1102},{"period":"6month","weight":0.2034},{"period":"1year","weight":0.1802},{"period":"ytd","weight":0.1627}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江佐力药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38581人(较上一季度增加0.92%)","perCapita":"15627股","listingDate":"2011-02-22","address":"浙江省湖州市德清县阜溪街道志远北路388号","registeredCapital":"70138万元","survey":" 浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵系列(乌灵胶囊、灵泽片、灵莲花颗粒)、百令系列(百令片、百令胶囊)、中药饮片及中药配方颗粒、聚卡波非钙片。2025年7月,由北京市经济和信息化局等单位联合主办、中国医药工业信息中心承办的2025第42届全国医药工业信息年会,公司荣膺2025年中国医药工业企业社会责任优秀案例榜单。","listedPrice":23.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佐力药业,300181,佐力药业股票,佐力药业股票老虎,佐力药业股票老虎国际,佐力药业行情,佐力药业股票行情,佐力药业股价,佐力药业股市,佐力药业股票价格,佐力药业股票交易,佐力药业股票购买,佐力药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}